In this sense, Voron and colleagues demonstrated that VEGF-A increases the percentages of TIM-3+-expressing CD8+ T cells and highlighted the role of VEGF-A in resistance to anti-PD-1 treatment in a murine model of colorectal cancer (26). This evidence concerns the gene HAVCR2 and colorectal cancer.